Viridian Therapeutics, Inc.
VRDN
$12.38
-$0.43-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -308.32M | -269.95M | -257.08M | -228.06M | -218.13M |
| Total Depreciation and Amortization | 1.21M | 1.24M | 1.57M | 1.37M | 1.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.66M | 26.79M | 43.78M | 50.72M | 57.46M |
| Change in Net Operating Assets | 701.00K | 9.60M | 14.75M | 7.70M | -8.12M |
| Cash from Operations | -279.75M | -232.32M | -196.99M | -168.26M | -167.42M |
| Capital Expenditure | -597.00K | -511.00K | -445.00K | -556.00K | -783.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.05M | -228.14M | -335.00M | -202.18M | -223.22M |
| Cash from Investing | 14.46M | -228.65M | -335.45M | -202.74M | -224.00M |
| Total Debt Issued | -- | -- | 0.00 | 15.00M | 15.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 281.64M | 459.68M | 557.39M | 323.19M | 326.05M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 25.00M | 25.00M | 101.19M | 76.19M | 76.19M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.77M | -26.94M | -37.43M | -22.79M | -22.69M |
| Cash from Financing | 289.87M | 457.74M | 621.15M | 391.59M | 394.55M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.57M | -3.23M | 88.72M | 20.59M | 3.13M |